In last trading session, Verve Therapeutics Inc (NASDAQ:VERV) saw 1.04 million shares changing hands with its beta currently measuring 1.75. Company’s recent per share price level of $7.70 trading at $0.45 or 6.21% at ring of the bell on the day assigns it a market valuation of $651.91M. That closing price of VERV’s stock is at a discount of -151.17% from its 52-week high price of $19.34 and is indicating a premium of 44.16% from its 52-week low price of $4.30. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.21 million shares which gives us an average trading volume of 1.69 million if we extend that period to 3-months.

For Verve Therapeutics Inc (VERV), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.40. Splitting up the data highlights that, out of 8 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.67 in the current quarter.

Verve Therapeutics Inc (NASDAQ:VERV) trade information

Upright in the green during last session for gaining 6.21%, in the last five days VERV remained trading in the red while hitting it’s week-highest on Thursday, 01/23/25 when the stock touched $7.70 price level, adding 11.49% to its value on the day. Verve Therapeutics Inc’s shares saw a change of 36.52% in year-to-date performance and have moved -1.28% in past 5-day. Verve Therapeutics Inc (NASDAQ:VERV) showed a performance of 22.22% in past 30-days. Number of shares sold short was 14.79 million shares which calculate 10.17 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 14 to the stock, which implies a rise of 45.0% to its current value. Analysts have been projecting 14 as a low price target for the stock while placing it at a high target of 14. It follows that stock’s current price would drop -81.82% in reaching the projected high whereas dropping to the targeted low would mean a loss of -81.82% for stock’s current value.

Verve Therapeutics Inc (VERV) estimates and forecasts

Statistics highlight that Verve Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 8.15% of value to its shares in past 6 months, showing an annual growth rate of 20.19% while that of industry is 17.30. Apart from that, the company came raising its revenue forecast for fiscal year 2025. This year revenue growth is estimated to rise 102.87% from the last financial year’s standing.

7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 4.24M for the same. And 5 analysts are in estimates of company making revenue of 3.79M in the next quarter. Company posted 5.14M and 5.7M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -67.06% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 22.10% while estimates for its earnings growth in next 5 years are of 2.28%.

Verve Therapeutics Inc (NASDAQ:VERV)’s Major holders

Insiders are in possession of 5.29% of company’s total shares while institution are holding 97.95 percent of that, with stock having share float percentage of 103.41%. Investors also watch the number of corporate investors in a company very closely, which is 97.95% institutions for Verve Therapeutics Inc that are currently holding shares of the company. ALPHABET INC. is the top institutional holder at VERV for having 12.35 million shares of worth $60.26 million. And as of 2024-06-30, it was holding 14.8546 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 6.62 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.9632 of outstanding shares, having a total worth of $32.31 million.

On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Nov 30, 2024 , the former fund manager was holding 2.3 shares of worth $17.73 million or 2.72% of the total outstanding shares. The later fund manager was in possession of 2.15 shares on Sep 30, 2024 , making its stake of worth around $16.59 million in the company or a holder of 2.54% of company’s stock.